Evidence map›Paper›PMID 25369284›Full record

ArticlePloS one2014

An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies.

Graziela S Ceravolo, Augusto C Montezano, Maria T Jordão, Eliana H Akamine, Tiago J Costa, Ana P Takano, Denise C Fernandes, Maria L Barreto-Chaves, Francisco R Laurindo, Rita C Tostes and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Bradykinin/BPhysiological reports · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Graziela S CeravoloDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil; Department of Physiological Sciences, Biological Sciences Center, State University of Londrina, Londrina, Brazil.
Augusto C MontezanoOttawa Health Research Institute, Kidney Research Centre, University of Ottawa, Ottawa, Canada; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Maria T JordãoDepartment of Anatomy, Institute of Biomedical Sciences III, University of São Paulo, Sao Paulo, Brazil.
Eliana H AkamineDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Tiago J CostaDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Ana P TakanoDepartment of Anatomy, Institute of Biomedical Sciences III, University of São Paulo, Sao Paulo, Brazil.
Denise C FernandesVascular Biology Laboratory, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Maria L Barreto-ChavesDepartment of Anatomy, Institute of Biomedical Sciences III, University of São Paulo, Sao Paulo, Brazil.
Francisco R LaurindoVascular Biology Laboratory, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Rita C TostesDepartment of Pharmacology, Ribeirão Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.
Zuleica B FortesDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Renato P ChopardDepartment of Anatomy, Institute of Biomedical Sciences III, University of São Paulo, Sao Paulo, Brazil.
Rhian M TouyzOttawa Health Research Institute, Kidney Research Centre, University of Ottawa, Ottawa, Canada; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Maria Helena C CarvalhoDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Universidade de São Paulo · BRUniversity of Glasgow · GBUniversidade Estadual de Londrina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kallikrein-kinin and renin-angiotensin systems interact at multiple levels. In the present study, we tested the hypothesis that the B1 kinin receptor (B1R) contributes to vascular hypertrophy in angiotensin II (ANG II)-induced hypertension, through a mechanism involving reactive oxygen species (ROS) generation and extracellular signal-regulated kinase (ERK1/2) activation. Male Wistar rats were infused with vehicle (control rats), 400 ng/Kg/min ANG II (ANG II rats) or 400 ng/Kg/min ANG II plus B1 receptor antagonist, 350 ng/Kg/min des-Arg(9)-Leu(8)-bradykinin (ANGII+DAL rats), via osmotic mini-pumps (14 days) or received ANG II plus losartan (10 mg/Kg, 14 days, gavage - ANG II+LOS rats). After 14 days, ANG II rats exhibited increased systolic arterial pressure [(mmHg) 184 ± 5.9 vs 115 ± 2.3], aortic hypertrophy; increased ROS generation [2-hydroxyethidium/dihydroethidium (EOH/DHE): 21.8 ± 2.7 vs 6.0 ± 1.8] and ERK1/2 phosphorylation (% of control: 218.3 ± 29.4 vs 100 ± 0.25]. B1R expression was increased in aortas from ANG II and ANG II+DAL rats than in aortas from the ANG II+LOS and control groups. B1R antagonism reduced aorta hypertrophy, prevented ROS generation (EOH/DHE: 9.17 ± 3.1) and ERK1/2 phosphorylation (137 ± 20.7%) in ANG II rats. Cultured aortic vascular smooth muscle cells (VSMC) stimulated with low concentrations (0.1 nM) of ANG II plus B1R agonist exhibited increased ROS generation, ERK1/2 phosphorylation, proliferating-cell nuclear antigen expression and [H3]leucine incorporation. At this concentration, neither ANG II nor the B1R agonist produced any effects when tested individually. The ANG II/B1R agonist synergism was inhibited by losartan (AT1 blocker, 10 µM), B1R antagonist (10 µM) and Tiron (superoxide anion scavenger, 10 mM). These data suggest that B1R activation contributes to ANG II-induced aortic hypertrophy. This is associated with activation of redox-regulated ERK1/2 pathway that controls aortic smooth muscle cells growth. Our findings highlight an important cross-talk between the DABK and ANG II in the vascular system and contribute to a better understanding of the mechanisms involved in vascular remodeling in hypertension.

Indexed as

Angiotensin IIAnimalsAntihypertensive AgentsAortaBlood PressureBradykinin B1 Receptor AntagonistsCells, CulturedDrug SynergismHypertensionHypertrophyKallikrein-Kinin SystemLosartanMaleMyocytes, Smooth MuscleRatsRats, WistarAngiotensin IIAntihypertensive AgentsBradykinin B1 Receptor AntagonistsLosartanReactive Oxygen SpeciesReceptor, Bradykinin B1Superoxides

Identifiers

PMID25369284
PMCPMC4219703
OpenAlexW2007133866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.